Tailored CRO Avastus Preclinical Services offers a broad suite of drug research services and disease models, positioning them as a flexible partner for startups and virtual R&D teams seeking to extend their operating runway and de-risk early-stage programs.

Operational Capabilities The company provides infrastructure and housing, along with IACUC support and protocol review, enabling clients to conduct experiments efficiently without building in-house facilities, which is especially appealing to small to mid-size biotech firms.

Diverse Disease Models A wide array of disease models including microbial infections, metabolic diseases, arthritis, rare genetic conditions, and patient derived xenografts offers opportunities to cross-sell multiple programs to the same client as their programs evolve.

Funding Extension By emphasizing runway extension and support through regulatory navigation and infrastructure, Avastus can target financially stretched startups and virtual groups, presenting themselves as a cost-efficient route to advance preclinical programs.

Growth Leap Potential With revenue in the mid single to upper mid range and a lean team, there is an opportunity to upsell additional services, expanded model portfolios, and high-margin offerings to similar CROs and mid-sized biotechs looking for scalable preclinical support.